Progressive Supranuclear Palsy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Conditions: Progressive Supranuclear Palsy Interventions: Drug: FNP-223; Drug: Placebo Sponsors: Ferrer Internacional S.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
Conditions: Progressive Supranuclear Palsy Interventions: Drug: GV1001 Placebo; Drug: GV1001 1.12mg Sponsors: GemVax& Kael Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials

Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study
Conditions: Neurodegenerative Diseases; Alzheimer Disease; Frontotemporal Dementia; Lewy Body Disease; Vascular Dementia; Parkinson Disease; Progressive Supranuclear Palsy; Corticobasal Degeneration; Multiple System Atrophy; Amyotrophic Lateral Sclerosis; Huntington Disease Sponsors: Kuopio University Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials

NYSCF Scientific Discovery Biobank
Conditions: ALS; Amyotrophic Lateral Sclerosis; Alzheimer Disease; Alzheimer Disease, Early Onset; Alzheimer Disease, Late Onset; Batten Disease; Corticobasal Degeneration; Dementia; Frontotemporal Dementia; Huntington Disease; Lewy Body Disease; Multiple Sclerosis; Multiple System Atrophy; Parkinson Disease; Parkinson ' s Disease and Parkinsonism; Progressive Supranuclear Palsy; INAD; Diabetes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1; Macular Degeneration; Ovarian Cancer; Cervical Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer; PTSD; Post Traumatic Stress Disorder Interventions: Othe...
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials

The Use of the CUE1 in People With Parkinson's Disease and Related Disorders
Conditions: Parkinson ' s Disease and Parkinsonism; Progressive Supranuclear Palsy; Tremor; Dystonia; Multiple System Atrophy; Corticobasal Degeneration; Vascular Parkinsonism Interventions: Device: CUE1 non-invasive device Sponsors: Queen Mary University of London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 18, 2023 Category: Research Source Type: clinical trials

The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism
Conditions: Progressive Supranuclear Palsy; Multiple System Atrophy; Corticobasal Syndrome Interventions: Dietary Supplement: Nicotinamide Riboside; Other: Placebo Sponsors: Haukeland University Hospital; Oslo universitetssykehus HF; Akershus Universitetssykehus HF; Vestre Viken HF; Sykehuset Østfold HF; Nevro Arendal AS; Helse Førde HF; Helse Fonna HF; Universitetssykehuset Nord Norge HF; Helse Møre og Romsdal HF; Nordlandssykehuset HF Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials

Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes
Conditions: Parkinson Disease; Progressive Supranuclear Palsy Interventions: Procedure: 7 Tesla MRI Sponsors: Assistance Publique Hopitaux De Marseille Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2023 Category: Research Source Type: clinical trials

AMX0035 and Progressive Supranuclear Palsy
Conditions: Progressive Supranuclear Palsy; PSP; Neurodegenerative Diseases; Atypical Parkinsonism Interventions: Drug: AMX0035; Other: Placebo Sponsors: Amylyx Pharmaceuticals Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials

GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
Condition: Progressive Supranuclear Palsy Interventions: Drug: GV1001 Placebo; Drug: GV1001 0.56mg; Drug: GV1001 1.12mg Sponsor: GemVax & Kael Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2023 Category: Research Source Type: clinical trials